

1 **Title:**

2 Sedentarism, physical activity, steps, and neurotrophic factors in obese children

3 **Authors' names:**

4 Jose Mora-Gonzalez<sup>1\*</sup>, Jairo H. Migueles<sup>1</sup>, Irene Esteban-Cornejo<sup>2,1</sup>, Cristina Cadenas-  
5 Sanchez<sup>1</sup>, Belén Pastor-Villaescusa<sup>3,4</sup>, Pablo Molina-García,<sup>1</sup> Maria Rodríguez-Ayllon<sup>1</sup>,  
6 María C. Rico<sup>4</sup>, Angel Gil<sup>4,5,6</sup>, Concepción M. Aguilera<sup>4,5,6</sup>, María Victoria Escolano-  
7 Margarit,<sup>7</sup> Anne Kaer Gejl<sup>8</sup>, Lars Bo Andersen<sup>9</sup>, Andrés Catena<sup>10</sup>, Francisco B. Ortega<sup>1</sup>.

8 **Authors' affiliations:**

9 <sup>1</sup>PROFITH “PROmoting FITness and Health through physical activity” Research Group,  
10 Department of Physical and Sports Education, Faculty of Sports Science, University of  
11 Granada, Spain. <sup>2</sup>Department of Psychology, Northeastern University, Boston,  
12 Massachusetts, USA. <sup>3</sup>LMU - Ludwig-Maximilians-Universität München, Division of  
13 Metabolic and Nutritional Medicine, Dr. von Hauner Children’s Hospital, Univ. of  
14 Munich Medical Center, Munich, Germany. <sup>4</sup>Department of Biochemistry and Molecular  
15 Biology II, Institute of Nutrition and Food Technology “José Mataix”, Center of  
16 Biomedical Research, University of Granada, Granada, Spain. <sup>5</sup>Instituto de Investigación  
17 Biosanitaria ibs. Granada, Granada, Spain. <sup>6</sup>CIBER Fisiopatología de la Obesidad y la  
18 Nutrición (CIBEROBN), Madrid, Spain. <sup>7</sup>Hospital Universitario San Cecilio, Granada,  
19 Spain. <sup>8</sup>Department of Physiotherapy and Occupational Therapy, University College  
20 Copenhagen, Copenhagen, Denmark. <sup>9</sup>Western Norway University of Applied Sciences,  
21 Campus Sogndal, Faculty of Education, Arts and Sport, Norway. <sup>10</sup>Department of  
22 Experimental Psychology, Mind, Brain and Behaviour Research Centre (CIMCYC),  
23 University of Granada, Granada, Spain.

24 \*Corresponding author: Jose Mora-Gonzalez, Department of Physical and Sports  
25 Education, Faculty of Sports Science, University of Granada; Carretera de Alfacar, 21.  
26 Granada 18071, Spain; +(34) 958 24 66 51, fax: +(34) 958 24 94 28; email:  
27 [jmorag@ugr.es](mailto:jmorag@ugr.es)

28 **ABSTRACT**

29 **Purpose:** This study aimed to examine the associations of sedentary time, physical  
30 activity (PA) and step-related behaviors with neurotrophic growth factors. **Methods:** A  
31 total of 97 children with overweight/obesity aged 8-11 years participated in this study.  
32 Sedentary time, PA, and steps were measured by GT3X+ accelerometers in hip and non-  
33 dominant wrist. Estimates of light, moderate, vigorous, and moderate-to-vigorous PA  
34 (MVPA) were obtained. Steps/daytime, peak 60-, 30-, and 1-min cadence were  
35 computed. The time accumulated (min/day) in different cadence bands of steps was also  
36 computed from hip accelerometer. Plasma levels of brain-derived neurotrophic factor  
37 (BDNF), vascular endothelial growth factor (VEGF), and insulin growth factor-1 (IGF-  
38 1) were determined by the XMap technology (Luminex IS 100/200 system, Luminex  
39 Corporation, Austin, TX). **Results:** Light PA, moderate PA, MVPA and the peak 60-min  
40 cadence were positively related with BDNF concentrations (all  $P < 0.05$ ), and only light  
41 PA to VEGF ( $P = 0.048$ ). No association was observed for IGF-1 ( $P > 0.05$ ). The  
42 associations of light PA with BDNF and VEGF disappeared (all  $P > 0.05$ ) after performing  
43 analyses with non-dominant wrist-placement data. However, moderate PA and MVPA  
44 remained significantly associated with BDNF (both  $P < 0.05$ ). The time accumulated in  
45 cadence bands of 40-59 steps/min and 60-79 steps/min (i.e., walking at slow pace) was  
46 positively associated with plasma BDNF (all  $P < 0.05$ ). **Conclusion:** In conclusion, PA is  
47 positively related to plasma BDNF, whereas no relationship was observed for VEGF or  
48 IGF-1. Higher amounts of time spent in slow walking cadence bands could increment  
49 BDNF levels. Exercise-based randomized controlled trials in children with  
50 overweight/obesity should be carried out to better understand the influence of PA  
51 behaviors on the neurotrophic factors.

52 **Key words:** accelerometry; BDNF; cognition; obesity; walking; youth

## 53 INTRODUCTION

54 Childhood obesity has shown to be negatively related to cognitive functions and  
55 detectable structural abnormalities in the brain (2,1). Likewise, obesity may also  
56 influence stored and circulating neurotrophic factors such as brain-derived neurotrophic  
57 factor (BDNF) in humans (3), although literature to this respect is inconsistent (4). It has  
58 been observed that BDNF missense mutations in its receptor, TrkB, have been associated  
59 with weight gain both in humans (4). Further, evidence have shown a significant  
60 reduction of circulating BDNF levels in children with obesity compared to normal-weight  
61 peers (5,6). Importantly, BDNF plays a key role in synaptic plasticity, neuronal  
62 transmission, and cell growth and survival throughout the cortex (7). This factor is  
63 produced in the brain and in selected peripheral tissues such as platelets (8). Platelets are  
64 the major non-neural source of BDNF from which it reaches plasma and is able to pass  
65 the blood-brain barrier, only when it is not bound to platelets (10,9). Interestingly, the  
66 positive correlation between BDNF in the brain and circulating BDNF suggests that  
67 circulating BDNF levels may reflect the levels in the central nervous system (11).  
68 Furthermore, BDNF may be released from the brain to the periphery during the practice  
69 of physical activity (PA) (12). Apart from BDNF, other neurotrophic factors such as  
70 vascular endothelial growth factor (VEGF) or insulin growth factor-1 (IGF-1) are  
71 important for neural growth and neuron survival (13). Hence, it seems of relevance to  
72 examine how protective environmental factors, such as lifestyle behaviors (e.g.,  
73 sedentarism or PA), may influence neurotrophic factors in a particularly vulnerable  
74 population such as children with overweight/obesity.

75 Emerging evidence suggest that PA has a beneficial effect on the brain and  
76 cognitive processes in children (14). Neurotrophic factors have been suggested as  
77 potential mechanisms underlying this relationship (15). From all these factors, BDNF

78 may be the most important one that has been suggested to be upregulated by PA (13).  
79 Indeed, BDNF may play a crucial role in the PA's influence on brain structure and as an  
80 underlying factor of the PA-induced cognitive improvement. However, in humans, there  
81 is inconsistent evidence on the role of PA on neurotrophic factors (19,18,17,16). PA may  
82 increment serum BDNF concentrations in adolescents (19,16) and adults (18), although  
83 there are other studies showing a negative association between PA and BDNF (17). In  
84 children, to the best of our knowledge, there are only two observational studies and they  
85 did not find significant associations (20,21). However, no previous cross-sectional studies  
86 have focused on obese children nor have analyzed the role of step-related behaviors on  
87 neurotrophic factors. In addition, the BDNF plays a key role in the energy homeostasis  
88 and the appetite regulation (22), which highlights even more the importance of examining  
89 the potential relationship of sedentary time and PA with brain in the context of obesity  
90 during childhood. Particularly, walking (hereinafter step-related behaviors) is the most  
91 popular PA behavior, as well as the ideal PA intervention to improve health across  
92 sedentary populations, such as the obese ones (23,24). Thus, the aim of the present study  
93 was to analyze the association of sedentary time, PA and step-related behaviors with  
94 BDNF and other neurotrophic factors (i.e., VEGF and IGF-1) in children with  
95 overweight/obesity.

## 96 **METHODS**

97 **Participants.** The present cross-sectional study was developed under the  
98 framework of the ActiveBrains project (<http://profith.ugr.es/activebrains>) (25). A total of  
99 110 children with overweight/obesity aged 8–11 years were recruited from Granada  
100 (Spain) after meeting the defined inclusion criteria, which have been described elsewhere  
101 (25). The study was conducted in three waves. The present cross-sectional analyses used  
102 baseline data from 97 children with overweight/obesity ( $10.0 \pm 1.2$  years old; 58% boys)

103 with complete baseline data on sedentary time, time-based PA, steps-related behaviors,  
104 and neurotrophic factors. For VEGF analyses, a sample of 88 participants was used after  
105 excluding those children with lower VEGF levels than the kit could detect. The baseline  
106 data collection took part from November 2014 to February 2016.

107 A description of the purpose and characteristics of the study was given to the  
108 parents or legal guardian and written informed consent was provided by them allowing  
109 the child to participate. The ActiveBrains project was approved by the Ethics Committee  
110 on Human Research of the University of Granada, and was registered in  
111 ClinicalTrials.gov (identifier: NCT02295072).

112 **Sedentary time, physical activity, and steps metrics.** Sedentary time, PA, and  
113 step-related behaviors were assessed by accelerometer (GT3X+, ActiGraph, Pensacola,  
114 FL, USA) taking into account the latest advances in data processing (26). Children wore  
115 simultaneously two accelerometers located on the right hip and non-dominant wrist for 7  
116 consecutive days (24h/day). They were instructed to remove them only for water  
117 activities (i.e., bathing or swimming) and to record waking-up and sleep onset times  
118 during the 7 days on a diary. Raw data were collected at a sampling frequency of 100 Hz  
119 were loaded in ActiLife (ActiGraph, Pensacola, FL, USA) and processed then in R (v.  
120 3.1.2, [https:// www.cran.r-project.org/](https://www.cran.r-project.org/)) using the GGIR package (v. 1.6-0, [https://cran.r-](https://cran.r-project.org/web/packages/GGIR/)  
121 [project.org/web/packages/GGIR/](https://cran.r-project.org/web/packages/GGIR/)) (27). We calculated the Euclidean Norm Minus One  $G$   
122 metric (ENMO,  $1 G \sim 9.8 \text{ m/s}^2$ ) after auto-calibrating the acceleration signal (27,28). The  
123 mean of ENMO with negative values rounded to zero was calculated over 5 s epochs.  
124 Simultaneously, we derived the number of steps/minute (step cadence) from the hip-worn  
125 accelerometer using the ActiLife software. Then, we imported steps information to R for  
126 further analyses in the GGIR package.

127 Accelerometric information processing in GGIR consisted in: a) Non-wear time  
128 detection by the Van Hees et al. approach (29). b) Detection of abnormally and sustained  
129 high acceleration values (i.e., clipped time). c) Replacement of the non-wear and clipped  
130 time by the mean acceleration recorded within the same time frame for the rest of the  
131 measurement (29). A replacement by 0 for all metrics was performed if no data were  
132 collected for a specific time frame for the rest of the days. d) Identification of waking and  
133 sleeping hours based on an automatized algorithm guided by the diaries completed by the  
134 participants (30). The inclusion criterion for a valid day was wearing the accelerometer  
135  $\geq 16$  h/day. A minimum of 4 valid days (3 weekdays and 1 weekend day) per week was  
136 required to be included in the analyses. The compliance wearing the accelerometer was  
137 high, with 98% of the sample wearing the accelerometers for  $\geq 6$  days.

138 Sedentary time and PA were classified into different intensities following  
139 Hildebrand et al. hip- and wrist-based cut-off points for the ENMO metric (31,32). Since  
140 ActiGraph's step detection algorithm is adapted to the hip location, the main analyses of  
141 the present study were performed using hip data, although analyses for sedentary time  
142 and PA were replicated using estimates from the non-dominant wrist-worn accelerometer  
143 and presented as supplementary material.

144 The PA variables included in this study were total minutes per day at light,  
145 moderate, vigorous, and MVPA for hip and wrist. With regards to steps, the volume of  
146 steps/day and the peak 60-, 30-, and 1-min cadences were computed following previously  
147 published procedures (33). We also derived time spent in the following cadence bands  
148 intensities (i.e., steps/min): 0 (Non-movement), 1–19 (Incidental movement), 20–39  
149 (Sporadic movement), 40–59 (Purposeful movement), 60–79 (Slow walking), 80–99  
150 (Medium walking), 100–119 (Brisk walking), and 120+ steps/min (Faster locomotor  
151 movements, e.g., running) (33).

152           **Neurotrophic factors.** Blood samples were obtained for biochemical and  
153 hematological screening tests between 08.30 AM and 10.30 AM after a minimum of 8  
154 hours overnight fasting condition at the San Cecilio University Hospital and the Virgen  
155 de las Nieves Maternity Hospital (Granada, Spain). All participants had up to 11 ml of  
156 blood drawn from the antecubital vein. The blood for plasma samples was drawn into  
157 tubes containing ethylenediaminetetraacetic acid (EDTA) and kept on ice for around 60  
158 min. After collection and transportation of the samples, they were centrifuged (10 min at  
159 4°C, 1000xg), aliquoted under cold conditions by ice, and immediately stored at -80°C in  
160 the Center of Biomedical Research (Granada, Spain) until analysis.

161           The analysis of mature BDNF, VEGF, and IGF-1 levels in plasma was performed  
162 using the Luminex IS 100/200 system (Luminex Corporation, Austin, TX, USA) with the  
163 XMap technology and using human monoclonal anti-bodies (Milliplex Map Kit,  
164 Millipore, Billerica, MA, USA). For mature BDNF, we used the Human  
165 Neurodegenerative Disease Magnetic Bead Panel 3 (Catalog #HNDG3MAG-36K; EMD  
166 Millipore Corporation, Billerica, MA, USA); for VEGF, we used the Human  
167 Angiogenesis/Growth Factor Magnetic Bead Panel (Catalog #HAGP1MAG-12K; EMD  
168 Millipore), and for IGF-1, we used the Human IGF-1, II Magnetic Bead Panel (Catalog  
169 #HIGFMAG-52K; EMD Millipore). In the Luminex IS 100/200 system, assay  
170 sensitivities or minimum detectable concentrations for BDNF, VEGF-A, and IGF-1  
171 assays were 0.23 ng/ml, 8.1 pg/ml, and 15 ng/ml, respectively. Those samples not  
172 reaching the minimum detectable were excluded from the analyses. The intra-assay %  
173 coefficient of variation for BDNF, VEGF-A, and IGF-1 was estimated to be <5.4, 3.5 and  
174 10, respectively, and inter-assay at <5.3, 10, 15, respectively.

175           **Potential confounders.** After testing with correlation analyses which of the  
176 variables could be a potential confounder, sex, peak height velocity (PHV), fat mass



177 index, wave of participation, and the parental educational level were used as potential  
178 confounders in the analyses. PHV is an indicator of maturity offset during childhood and  
179 adolescence (34). We used age and anthropometric variables (height –girls- and seated  
180 height -boys-) to calculate PHV following Moore’s equations (34). The difference in  
181 years between PHV and chronological age was defined as a value of maturity offset. Fat  
182 mass index ( $\text{kg}/\text{m}^2$ ) was assessed by Dual-energy X-ray absorptiometry (DXA, Discovery  
183 densitometer from Hologic). Wave of participation was a categorical variable according  
184 to the first moment of participation of each child in the study (wave 1, 2, or 3). Parental  
185 educational level was assessed by a self-reported questionnaire completed by parents, and  
186 we combined responses of both of them as: neither had a university degree; one had a  
187 university degree; or both had a university degree (35).

188 **Statistical analysis.** The characteristics of the study sample are presented as  
189 means and standard deviations (SD) or percentages. Non-normally distributed outcomes  
190 are presented as median and interquartile range (IQR). Prior to all analyses, the extreme  
191 values were winsorized to limit their influence; this was done by replacing raw scores  
192 with less than the 1<sup>st</sup> percentile of the cohort-wide distribution with the value of the 1<sup>st</sup>  
193 percentile and replacing scores greater than the 99<sup>th</sup> percentile with the 99<sup>th</sup> percentile  
194 value (36). Furthermore, all outcomes were checked for normal distribution and BDNF,  
195 VEGF, and IGF-1 were normalized since they showed skewed distributions. Interaction  
196 analyses were performed between sex and sedentary time, PA and steps-related behaviors  
197 on the neurotrophic factors. No significant interactions with sex were found ( $P \geq 0.10$ );  
198 therefore, analyses were performed for all the participants together.

199 Linear regression analyses were performed to examine the association of  
200 estimations from hip-worn accelerometers of sedentary time, PA, and step-related  
201 behavior with neurotrophic factors (i.e., BDNF, VEGF and IGF-1) adjusting by potential

202 confounders. Sedentary time and PA analyses were replicated for the non-dominant wrist-  
203 placement data. We also performed linear regression analyses to examine the association  
204 between time accumulated (min/day) in different cadence bands of 0, 1–19, 20–39, 40–  
205 59, 60–79, 80–99, 100–119, and 120+ steps/min and the BDNF, adjusting by potential  
206 confounders. We performed collinearity diagnosis between physical activity intensities  
207 and between step cadences. No multi-collinearity was observed among any of the  
208 independent variables (variance inflation factor, VIF < 10). A significance level of  $P < 0.05$   
209 was used. All the statistical procedures were performed using the SPSS software for Mac  
210 (version 22.0, IBM Corporation).

## 211 RESULTS

212 Descriptive characteristics of the sample are shown in **Table 1**. Times  
213 accumulated at different cadence bands are shown in **Table 2**. A significant association  
214 was found between light PA, moderate PA, MVPA, and peak 60-min steps cadence with  
215 BDNF ( $\beta$  ranging from 0.195 to 0.242, all  $P < 0.037$ ) (**Table 3**). An association was also  
216 found between light PA and VEGF ( $\beta = 0.207$ ,  $P = 0.048$ ). No significant associations were  
217 found for the relationship of sedentary time with any of the neurotrophic factors nor for  
218 the relationship between PA, step-related behaviors, and IGF-1 ( $P > 0.05$ ). When  
219 performing analyses with non-dominant wrist-placement data (**Table S1**), the  
220 associations of light PA with BDNF and VEGF disappeared (all  $P > 0.05$ ). However,  
221 moderate PA and MVPA remained significantly associated with BDNF ( $\beta = 0.220$ ,  
222  $P = 0.041$  and  $\beta = 0.246$ ,  $P = 0.027$ , respectively). An association was also observed between  
223 vigorous PA and BDNF ( $\beta = 0.244$ ,  $P = 0.032$ ).

224 **Figure 1** shows the relationship between time accumulated at different steps  
225 cadence bands and BDNF, adjusting for potential confounders. Among all the cadence

226 bands, a significant association was found for the time spent in the 40-59 steps/min  
227 cadence band (i.e., Purposeful movement) and the time spent in 60-79 steps/min cadence  
228 band (i.e., Slow walking) with BDNF ( $\beta=0.198$ ,  $P=0.044$ , and  $\beta=0.205$ ,  $P=0.040$ ,  
229 respectively).

## 230 **DISCUSSION**

231 The main finding of the present study was that objectively-measured PA and step-  
232 related behaviors, but not sedentary time, were positively associated with BDNF in  
233 children. Particularly, light PA, moderate PA, MVPA, and peak 60-min steps cadency  
234 were related to BDNF, being the associations of moderate PA and MVPA consistent from  
235 either hip or wrist accelerometer data. No significant associations were found between  
236 PA and steps with VEGF and IGF-1, apart from the borderline association observed  
237 between light PA and VEGF. No association was found between sedentary time and the  
238 neurotrophic factors. In addition, the time spent in purposeful movements (i.e., 40–59  
239 steps/min) and slow walking (i.e., 60–79 steps/min) was associated with BDNF. Our  
240 findings suggest that different intensities and types of PA, mainly moderate and MVPA  
241 and walking at slow-medium cadences may increase plasma BDNF levels in children  
242 with overweight/obesity. However, these findings must be interpreted with caution due  
243 to the methodological limitations when measuring neurotropic factors (37), as well as to  
244 the complexity of PA analyses and the emerging variety of methods to analyze it (26).

245 To the best of our knowledge, this is the first study that analyzes the association  
246 between objectively-measured sedentary time, PA and step-related behaviors with  
247 neurotrophic factors (i.e., BDNF, VEGF and IGF-1) in a sample of children with  
248 overweight/obesity. Only two observational studies in healthy normal-weight children  
249 have previously analyzed this relationship. In line with our results, Gabel et al. did not

250 find any association between sedentary time and plasma BDNF levels in 7–10-year-old  
251 children (21). In contrast to our cross-sectional results, a recent 2-year longitudinal study  
252 did not find a relationship between objectively-measured PA and serum BDNF in children  
253 aged 8–11 years (20). When analyzing steps, our positive results between the peak 60-  
254 min cadence and BDNF are in contrast to the negative associations found by another  
255 study in adults (38). The inconsistency and contradictory findings regarding the  
256 relationship between PA, steps and BDNF might be due to differences between studies  
257 with respect to the sample’s characteristics (i.e., overweight/obese versus normal weight  
258 peers); the age group analyzed (i.e., children versus adolescents or adults); the study  
259 design (i.e., cross-sectional versus longitudinal); and the methodology followed for  
260 assessing and processing PA (i.e., objective versus subjective methods) or for analyzing  
261 the neurotrophic factors levels (i.e., differences regarding kits used, pre-storage  
262 treatments of blood samples –clotting/icing time, centrifugation strategy– or the way  
263 BDNF is measured in peripheral blood –plasma BDNF versus serum BDNF). With  
264 respect to the differences in BDNF measurements, much higher concentrations of BDNF  
265 has been observed in serum in comparison to plasma (8,39). On one hand, the clotting  
266 time methodology chosen can be critical for serum BDNF levels (8,40). On the other  
267 hand, plasma is obtained from blood samples drawn into tubes containing anti-coagulants,  
268 preventing coagulation and thereby activation of platelets and BDNF release. Due to the  
269 smaller amount of platelet-associated BDNF in plasma, BDNF measured in plasma may,  
270 to a higher extent than serum BDNF, reflect the concentration of free BDNF. However,  
271 there is still a need to better understand how much it reflects brain levels and how it relates  
272 to PA.

273           Despite findings from most observational studies suggest an inverse relationship  
274 between PA and peripheral BDNF levels (18), the positive associations found in our study

275 are supported by previous literature focusing on the effects of physical exercise on BDNF  
276 in humans (18,41). Particularly, two studies analyzed the changes in children's BDNF  
277 level after a lifestyle intervention which included an exercise component. Corripio et al.  
278 (42) observed that BDNF in plasma was increased in prepubertal obese children after a  
279 2-year lifestyle intervention which included 30 to 45 min of moderate exercise 3 times  
280 per week. On the contrary, another study did not find any significant change in serum  
281 BDNF in children of different weight loss after one-year exercise therapy (i.e., physical  
282 games) once per week (6). In adults, a recent meta-analysis showed that both acute and  
283 regular programmed exercise had a significant impact on BDNF concentrations,  
284 reflecting a moderate and small effect size (Hedges'g=0.46, P<0.001; and  
285 Hedges'g=0.28, P=0.005, respectively for acute and regular exercise intervention studies)  
286 (41). Another study found that the impact on adult's BDNF levels might be exercise  
287 intensity-dependent (19). In fact, we observed a significant association between vigorous  
288 PA and BDNF when the wrist-location data was used. No information is yet available  
289 regarding which accelerometer-location is more valid and reliable in children (26), what  
290 highlight the need of reporting both hip and wrist data whenever this is feasible. In our  
291 study, moderate PA and MVPA intensities were consistently associated with BDNF when  
292 using either hip or wrist PA data. This fact suggest that a moderate intensity of PA could  
293 be a higher stimulus for children with overweight/obesity to increase BDNF levels.  
294 However, further investigations are needed in order to clarify the effects of different PA  
295 intensities accelerometer-locations on neurotrophic factors.

296 Another interesting finding of this study was the consistently (with both hip and  
297 wrist data) no significant associations between sedentary time, PA and steps with VEGF  
298 and IGF-1 (only a borderline association was found between light PA and VEGF).  
299 Although BDNF, VEGF and IGF-1 are all considered neurotrophic factors and have

300 several characteristics in common, each of them has a different functionality. Whereas  
301 BDNF is an important nerve growth factor that facilitates the growth and survival of  
302 various neurons and regulates synaptic plasticity (7), both VEGF and IGF-1 contribute to  
303 the stimulation of angiogenesis and hippocampal neurogenesis (13). Thus, the influence  
304 of PA may be different depending on the factor, what could explain the significant  
305 associations found for BDNF and the non-associations for VEGF and IGF-1.

306         When analyzing which of the steps cadence bands were associated to BDNF, we  
307 observed a significant association of the time accumulated in purposeful movement (i.e.,  
308 40–59 steps/min) and in slow walking (60–79 steps/min) with BDNF. In this regard,  
309 walking is the most popular PA behavior, as well as the ideal PA intervention to be  
310 recommended to improve health across sedentary populations, such as the one of the  
311 present study (23,24). Additionally, the fact that our sample only accumulate an average  
312 of 7.8 min/day in bands over 100 steps/min limits the possibility to detect any significant  
313 relation between these high cadences and BDNF. To the best of our knowledge, no  
314 previous studies have analyzed the relation between time in different cadence bands and  
315 neurotrophic factors. The cadence bands appearing significantly associated to BDNF in  
316 children with overweight/obesity could be considered as bands of light PA. This, together  
317 with the fact that we also found an association between light PA and BDNF, may suggest  
318 that light activities such as walking may be enough to increase levels of the BDNF in  
319 children with overweight/obesity. In fact, children with overweight/obesity have shown  
320 a higher metabolic cost when walking at same speeds in comparison with normal-weight  
321 peers (43). This fact may indicate that children with overweight/obesity could be more  
322 sensible to neurophysiological changes at lower absolute intensities, yet the relative  
323 intensity (e.g., % of maximal heart rate) might be similar to higher cadences conducted  
324 by leaner children. Additionally, obese children do not achieve cadences that are as high

325 as those reached by either overweight or normal-weight children, and therefore it may be  
326 difficult to investigate whether high cadences are associated with neurotrophic factors  
327 (33,43). Taking into account the difficulties to perform physical activities of higher  
328 intensity for this type of population, walking may be of help to increase total PA levels  
329 and health (24), and therefore have neurotrophic benefits (44).

330         Several explanations have been suggested in order to physiologically explain our  
331 associations between PA and BDNF.(18) First, BDNF can pass through the blood-brain  
332 barrier in both directions (10), and it may be speculated whether peripheral BDNF  
333 circulating in blood is more efficiently uptaken or released by the brain or platelets in  
334 physically active individuals (12). However, this must be interpreted with caution since  
335 platelets cannot pass the blood-brain barrier, and at least 80% of the BDNF in plasma  
336 comes from platelets (8). Second, exercise may have beneficial effects on platelet  
337 function, being platelets a main storage for peripheral BDNF (45). Third, aerobic exercise  
338 increases hippocampal levels of BDNF in animals (13). Animal models have also shown  
339 that BDNF can pass the blood-brain barrier from the brain to the plasma (10), and it is  
340 likely that exercise cause a production of BDNF in human brain. All these neurobiological  
341 mechanisms may explain the association of PA and steps with BDNF in the present study.  
342 However, further studies are needed to elucidate the underlying mechanisms on the  
343 association between PA and BDNF.

344         Caution must be applied when interpreting our findings due to several limitations.  
345 Firstly, the cross-sectional design does not allow inferences about causality to any of the  
346 associated outcomes. Secondly, plasma BDNF bound to platelets cannot cross the blood-  
347 brain barrier (46) and therefore the BDNF level in the brain may be rather reflected by  
348 the amount of free BDNF in plasma (not bounded to platelets) (39). Further, normal  
349 plasma still contains a large number of platelets after centrifugation, and since BDNF is

350 released from platelets due to activation (e.g. when a blood vessel is punctured), this fact  
351 may highly affect the level of BDNF in plasma measured in vitro (8). Thirdly, in our  
352 study we used a statistical approach to analyze PA that has been previously used in the  
353 literature focusing on neurotrophic factors and that allows us to make direct comparisons  
354 with previous studies. However, nowadays it is complex to choose a way to analyze PA,  
355 what is reflected in the wide variety of statistical approaches to analyze PA in the  
356 literature. Many of these ways to analyze PA should be performed when a large sample  
357 size is available, as they require all predictors (i.e., sedentary time, light physical activity,  
358 moderate physical activity and vigorous physical activity) coexisting in the same model,  
359 therefore decreasing the degrees of freedom and, also, the statistical power. Our relatively  
360 small sample (N = 97) discourage any attempt of applying statistical models requiring  
361 larger sample sizes to answer these questions. Thus, in order to find a consensus and  
362 clarify which is the best method to analyze PA, future studies using larger sample sizes  
363 should address different type of PA analysis when analyzing its association with  
364 neurotrophic factors. On the other hand, the main strength of this study was its novelty,  
365 being the first study to investigate the relationship between sedentary time, PA and steps  
366 with neurotrophic factors in a sample of children with overweight/obesity. Additional  
367 strengths include the objective measurements of sedentary time, PA and steps using raw  
368 accelerations in two different locations (hip and non-dominant wrist) and the use of the  
369 most advanced technology to analyze neurotrophic factors (i.e., Luminex 200).

## 370 **CONCLUSION**

371 The results of the present study suggest that light to moderate PA intensity and  
372 step-related behaviors, but not sedentary time, are positively associated to BDNF in  
373 children with overweight/obesity. Moderate PA and MVPA seem to be consistent in the  
374 association with BDNF regardless of the accelerometer location. Particularly, the time



375 spent in walking at slow cadences may be stimulus enough to influence the levels of  
376 BDNF in children with overweight/obesity. No associations were found between PA,  
377 sedentary time, and VEGF and IGF. Importantly, we revealed for the first time that light  
378 PA, moderate PA, MVPA and time spent in walking at slow cadences, but not sedentary  
379 time, were associated with BDNF in children with overweight/obesity. These findings  
380 shed light on that children in an overweight/obesity status may have more room for BDNF  
381 increments induced by physical activity. Further, walking at slow cadences may be  
382 stimulus enough for this population to influence levels of BDNF. Result from the present  
383 study must be interpreted with caution taking into account the limitations and variety of  
384 methods used to measure neurotrophic factors and to analyze PA. Thus, further studies  
385 using other methods must confirm or contrast our results.

#### 386 **ACKNOWLEDGEMENT**

387 The ActiveBrains project was funded by the Spanish Ministry of Economy and  
388 Competitiveness/FEDER (DEP2013-47540, DEP2016-79512-R, RYC-2011-09011).  
389 JM-G and JHM are supported by the Spanish Ministry of Education, Culture and Sport  
390 (FPU14/06837 and FPU15/02645, respectively). IE-C is supported by a grant from the  
391 Alicia Koplowitz Foundation. CC-S is supported by a grant from the Spanish Ministry of  
392 Economy and Competitiveness (BES-2014-068829). PM-G is supported by a grant from  
393 European Union's Horizon 2020 research and innovation program (No 667302).  
394 Additional support was obtained from the University of Granada, Plan Propio de  
395 Investigación 2016, Excellence actions: Units of Excellence, Unit of Excellence on  
396 Exercise and Health (UCEES); and by the Junta de Andalucía, Conserjería de  
397 Conocimiento, Investigación y Universidades and European Regional Development Fund  
398 (ERDF) (Ref. SOMM17/6107/UGR). In addition, funding was provided by the SAMID  
399 III network, RETICS, funded by the PN I+D+I 2017-2021 (Spain), ISCIII- Sub-

400 Directorate General for Research Assessment and Promotion, the European Regional  
401 Development Fund (ERDF) (Ref. RD16/0022) and the EXERNET Research Network on  
402 Exercise and Health in Special Populations (DEP2005-00046/ACTI). We would like to  
403 thank all the families participating in the ActiveBrains project. We also acknowledge  
404 everyone who helped with the data collection and all of the members involved in the field-  
405 work for their effort, enthusiasm, and support. This work is part of Ph.D. Thesis  
406 conducted in the Biomedicine Doctoral Studies of the University of Granada, Spain.

#### 407 **CONFLICT OF INTEREST**

408         The results of the present study do not constitute endorsement by ACSM. We  
409 declare that the results of the study are presented clearly, honestly, and without  
410 fabrication, falsification, or inappropriate data manipulation.

#### 411 **REFERENCES**

- 412 1.     Ou X, Andres A, Pivik RT, Cleves MA, Badger TM. Brain gray and white matter  
413 differences in healthy normal weight and obese children. *J Magn Reson Imaging*.  
414 2015;42(5):1205–13.
- 415 2.     Kamijo K, Pontifex MB, Khan NA, et al. The negative association of childhood  
416 obesity to cognitive control of action monitoring. *Cereb Cortex*. 2014;24(3):654–  
417 62.
- 418 3.     Lommatzsch M, Zingler D, Schuhbaeck K, et al. The impact of age, weight and  
419 gender on BDNF levels in human platelets and plasma. *Neurobiol Aging*.  
420 2005;26(1):115–23.
- 421 4.     Sandrini L, Di Minno A, Amadio P, Ieraci A, Tremoli E, Barbieri SS.  
422 Association between obesity and circulating brain-derived neurotrophic factor  
423 (BDNF) levels: Systematic review of literature and meta-analysis. *Int J Mol Sci*.


- 424 2018;19(8).
- 425 5. El-Gharbawy AH, Adler-Wailes DC, Mirch MC, et al. Serum brain-derived  
426 neurotrophic factor concentrations in lean and overweight children and  
427 adolescents. *J Clin Endocrinol Metab.* 2006;91(9):3548–52.
- 428 6. Roth CL, Elfers C, Gebhardt U, Müller HL, Reinehr T. Brain-derived  
429 neurotrophic factor and its relation to leptin in obese children before and after  
430 weight loss. *Metabolism.* 2013;62(2):226–34.
- 431 7. Binder DK, Scharfman HE. Brain-derived neurotrophic factor. *Growth Factors.*  
432 2004;22(3):123–31.
- 433 8. Fujimura H, Altar CA, Chen R, et al. Brain-derived neurotrophic factor is stored  
434 in human platelets and released by agonist stimulation. *Thromb Haemost.*  
435 2002;87(4):728–34.
- 436 9. Yamamoto H, Gurney ME. Human platelets contain brain-derived neurotrophic  
437 factor. *J Neurosci.* 1990;10(11):3469–78.
- 438 10. Pan W, Banks WA, Fasold MB, Bluth J, Kastin AJ. Transport of brain-derived  
439 neurotrophic factor across the blood-brain barrier. *Neuropharmacology.*  
440 1998;37(12):1553–61.
- 441 11. Klein AB, Williamson R, Santini MA, et al. Blood BDNF concentrations reflect  
442 brain-tissue BDNF levels across species. *Int J Neuropsychopharmacol.*  
443 2011;14(3):347–53.
- 444 12. Rasmussen P, Brassard P, Adser H, et al. Evidence for a release of brain-derived  
445 neurotrophic factor from the brain during exercise. *Exp Physiol.*  
446 2009;94(10):1062–9.
- 447 13. Cotman CW, Berchtold NC, Christie L-A. Exercise builds brain health: Key roles  
448 of growth factor cascades and inflammation. *Trends Neurosci.* 2007;30(9):464–

- 449 72.
- 450 14. Donnelly JE, Hillman CH, Castelli D, et al. Physical activity, fitness, cognitive  
451 function, and academic achievement in children: A systematic review. *Med Sci*  
452 *Sports Exerc.* 2016;48(6):1197–222.
- 453 15. Herting MM, Keenan MF, Nagel BJ. Aerobic fitness linked to cortical brain  
454 development in adolescent males: Preliminary findings suggest a possible role of  
455 BDNF genotype. *Front Hum Neurosci.* 2016;10:327.
- 456 16. Jeon YK, Ha CH. The effect of exercise intensity on brain derived neurotrophic  
457 factor and memory in adolescents. *Environ Health Prev Med.* 2017;22(1):27.
- 458 17. Huang T, Gejl AK, Tarp J, Andersen LB, Peijs L, Bugge A. Cross-sectional  
459 associations of objectively-measured physical activity with brain-derived  
460 neurotrophic factor in adolescents. *Physiol Behav.* 2016;171:87–91.
- 461 18. Huang T, Larsen KT, Ried-Larsen M, Møller NC, Andersen LB. The effects of  
462 physical activity and exercise on brain-derived neurotrophic factor in healthy  
463 humans: A review. *Scand J Med Sci Sports.* 2014;24(1):1–10.
- 464 19. Ferris LT, Williams JS, Shen C-L. The effect of acute exercise on serum brain-  
465 derived neurotrophic factor levels and cognitive function. *Med Sci Sport Exerc.*  
466 2007;39(4):728–34.
- 467 20. Arvidsson D, Johannesson E, Andersen LB, et al. A longitudinal analysis of the  
468 relationships of physical activity and body fat with nerve growth factor and  
469 brain-derived neural factor in children. *J Phys Act Heal.* 2018;1–6.
- 470 21. Gabel L, Ridgers ND, Della Gatta PA, et al. Associations of sedentary time  
471 patterns and TV viewing time with inflammatory and endothelial function  
472 biomarkers in children. *Pediatr Obes.* 2016;11(3):194–201.
- 473 22. Spaeth AM, Kanoski SE, Hayes MR, Grill HJ. TrkB receptor signaling in the

- 474 nucleus tractus solitarius mediates the food intake-suppressive effects of  
475 hindbrain BDNF and leptin. *Am J Physiol Endocrinol Metab.*  
476 2012;302(10):E1252-60.
- 477 23. Ding D, Nguyen B, Learnihan V, et al. Moving to an active lifestyle? A  
478 systematic review of the effects of residential relocation on walking, physical  
479 activity and travel behaviour. *Br J Sports Med.* 2018;52(12):789–99.
- 480 24. Morris JN, Hardman AE. Walking to health. *Sports Med.* 1997;23(5):306–32.
- 481 25. Cadenas-Sánchez C, Mora-González J, Migueles JH, et al. An exercise-based  
482 randomized controlled trial on brain, cognition, physical health and mental health  
483 in overweight/obese children (ActiveBrains project): Rationale, design and  
484 methods. *Contemp Clin Trials.* 2016;47:315–24.
- 485 26. Migueles JH, Cadenas-Sanchez C, Ekelund U, et al. Accelerometer data  
486 collection and processing criteria to assess physical activity and other outcomes:  
487 A systematic review and practical considerations. *Sports Med.* 2017;47(9):1821–  
488 1845.
- 489 27. van Hees VT, Gorzelniak L, Dean León EC, et al. Separating movement and  
490 gravity components in an acceleration signal and implications for the assessment  
491 of human daily physical activity. *PLoS One.* 2013;8(4):e61691.
- 492 28. van Hees VT, Fang Z, Langford J, et al. Autocalibration of accelerometer data for  
493 free-living physical activity assessment using local gravity and temperature: an  
494 evaluation on four continents. *J Appl Physiol.* 2014;117(7):738–44.
- 495 29. van Hees VT, Renström F, Wright A, et al. Estimation of daily energy  
496 expenditure in pregnant and non-pregnant women using a wrist-worn tri-axial  
497 accelerometer. *PLoS One.* 2011;6(7):e22922.
- 498 30. van Hees VT, Sabia S, Anderson KN, et al. A novel, open access method to

- 499 assess sleep duration using a wrist-worn accelerometer. *PLoS One*.  
500 2015;10(11):e0142533.
- 501 31. Hildebrand M, Hansen BH, van Hees VT, Ekelund U. Evaluation of raw  
502 acceleration sedentary thresholds in children and adults. *Scand J Med Sci Sports*.  
503 2016;27(12):1814–23.
- 504 32. Hildebrand M, Van Hees VT, Hansen BH, Ekelund U. Age group comparability  
505 of raw accelerometer output from wrist-and hip-worn monitors. *Med Sci Sport  
506 Exerc*. 2014;46(9):1816–24.
- 507 33. Barreira T V, Katzmarzyk PT, Johnson WD, Tudor-Locke C. Cadence patterns  
508 and peak cadence in US children and adolescents: NHANES, 2005-2006. *Med  
509 Sci Sports Exerc*. 2012;44(9):1721–7.
- 510 34. Moore SA, Mckay HA, Macdonald H, et al. Enhancing a somatic maturity  
511 prediction model. *Med Sci Sport Exerc*. 2015;47(8):1755–64.
- 512 35. Huppertz C, Bartels M, de Geus EJC, et al. The effects of parental education on  
513 exercise behavior in childhood and youth: A study in Dutch and Finnish twins.  
514 *Scand J Med Sci Sports*. 2017;27(10):1143–56.
- 515 36. Sink KM, Espeland MA, Castro CM, et al. Effect of a 24-month physical activity  
516 intervention vs health education on cognitive outcomes in sedentary older adults.  
517 *JAMA*. 2015;314(8):781.
- 518 37. Pareja-Galeano H, Alis R, Sanchis-Gomar F, et al. Methodological  
519 considerations to determine the effect of exercise on brain-derived neurotrophic  
520 factor levels. *Clin Biochem*. 2015;48(3):162–6.
- 521 38. Nofuji Y, Suwa M, Moriyama Y, et al. Decreased serum brain-derived  
522 neurotrophic factor in trained men. *Neurosci Lett*. 2008;437(1):29–32.
- 523 39. Radka SF, Holst PA, Fritsche M, Altar CA. Presence of brain-derived

- 524 neurotrophic factor in brain and human and rat but not mouse serum detected by  
525 a sensitive and specific immunoassay. *Brain Res.* 1996;709(1):122–301.
- 526 40. Tsuchimine S, Sugawara N, Ishioka M, Yasui-Furukori N. Preanalysis storage  
527 conditions influence the measurement of brain-derived neurotrophic factor levels  
528 in peripheral blood. *Neuropsychobiology.* 2014;69(2):83–8.
- 529 41. Szuhany KL, Bugatti M, Otto MW. A meta-analytic review of the effects of  
530 exercise on brain-derived neurotrophic factor. *J Psychiatr Res.* 2015;60:56–64.
- 531 42. Corripio R, González-Clemente J-M, Jacobo P-S, et al. Plasma brain-derived  
532 neurotrophic factor in prepubertal obese children: Results from a 2-year lifestyle  
533 intervention programme. *Clin Endocrinol (Oxf).* 2012;77(5):715–20.
- 534 43. Huang L, Chen P, Zhuang J, Walt S, Walt S. Metabolic cost, mechanical work,  
535 and efficiency during normal walking in obese and normal-weight children. *Res*  
536 *Q Exerc Sport.* 2013;84 Suppl 2(sup2):S72-9.
- 537 44. Shultz SP, Anner J, Hills AP. Paediatric obesity, physical activity and the  
538 musculoskeletal system. *Obes Rev.* 2009;10(5):576–82.
- 539 45. Tang SW, Chu E, Hui T, Helmeste D, Law C. Influence of exercise on serum  
540 brain-derived neurotrophic factor concentrations in healthy human subjects.  
541 *Neurosci Lett.* 2008;431(1):62–5.
- 542 46. de Vries HE, Kuiper J, de Boer AG, Van Berkel TJ, Breimer DD. The blood-  
543 brain barrier in neuroinflammatory diseases. *Pharmacol Rev.* 1997;49(2):143–55.
- 544



**Figure 1.** Relationship between time (min/day) accumulated at different cadence bands and levels of brain-derived neurotrophic factor (BDNF).

These analyses were adjusted for the following covariates: sex, peak height velocity, fat mass index, wave of participation and parental educational level. The asterisk (\*) is used to highlight significance level at  $P < 0.05$ .



**Table 1.** Descriptive characteristics of the study sample.

	All (n=97)	Boys (n=56)	Girls (n=41)
<b>Physical characteristics</b>			
Age (years)	10.1 ± 1.2	10.2 ± 1.2	9.9 ± 1.1
Peak height velocity offset (years)	-2.3 ± 1.0	-2.7 ± 0.8	-1.7 ± 1.0
Weight (kg)	56.0 ± 10.7	56.6 ± 10.3	55.2 ± 11.2
Height (cm)	144.1 ± 8.4	144.6 ± 7.9	143.5 ± 9.1
BMI (kg/m <sup>2</sup> )	26.8 ± 3.5	26.9 ± 3.6	26.6 ± 3.4
<b>BMI categories (%)*</b>			
Overweight	24	23	24
Obesity grade I	46	50	42
Obesity grade II	21	16	27
Obesity grade III	9	11	7
Fat mass index (kg/m <sup>2</sup> )	11.8 ± 2.8	11.5 ± 2.8	12.1 ± 2.8
<b>Wave of participation (%)</b>			
First	16.5	10.7	24.4
Second	42.3	50.0	31.7
Third	41.2	39.3	43.9
<b>Parental university level (%)</b>			
None of them	64.9	71.4	56.1
One of them	17.5	14.3	22.0
Both of them	17.5	14,3	22.0
Sedentary time (min/day)	818.3 ± 45.6	812.2 ± 44.1	826.7 ± 46.9
Physical activity (min/day)			

Light PA	65.3 ± 15.5	67.6 ± 15.1	62.1 ± 15.7
Moderate PA	32.4 ± 13.6	36.8 ± 14.5	26.4 ± 9.6
Vigorous PA	3.0 ± 2.1	3.7 ± 2.2	2.1 ± 1.4
MVPA	35.4 ± 14.1	40.5 ± 16.0	28.5 ± 10.6
Steps			
Volume (steps/day)	8588.6 ± 2176.7	9163.9 ± 2416.0	7802.9 ± 1499.5
Peak 60-min cadence (steps/min)	63.2 ± 13.1	66.1 ± 14.3	59.2 ± 10.2
Peak 30-min cadence (steps/min)	77.5 ± 14.0	79.5 ± 15.0	74.7 ± 12.1
Peak 1-min cadence (steps/min)	111.0 ± 13.0	111.2 ± 13.5	110.9 ± 12.5
Neurotrophic factors (median (IQR))			
BDNF (ng/ml)	3.0 (4.4)	3.0 (4.1)	2.9 (6.1)
VEGF (pg/ml)†	35.4 (35.9)	37.7 (34.8)	34.5 (51.1)
IGF-1 (ng/ml)	86.6 (38.8)	80.2 (39.4)	90.8 (52.7)

Values are means ± standard deviations, unless otherwise indicated. PA=Physical activity; MVPA=Moderate-to-Vigorous Physical Activity; BDNF=Brain-derived neurotrophic factor; VEGF=Vascular endothelial growth factor A; IGF-1=Insulin-like growth factor-1; BMI=body mass index. Sedentary time, physical activity and step-related behaviors were obtained from the Euclidian norm minus one metric in hip. \*BMI categories were defined (i.e. overweight, obesity grade I, II, III) according to Cole and Lobstein (2012). †Sample for VEGF was n=88 (n=55 boys; n=33 girls).

**Table 2.** Time (min/day) accumulated at different cadence band of steps.

	All (n=97)	Boys (n=56)	Girls (n=41)
Cadence bands (steps/min)			
Non-movement (0)	346.4 ± 79.7	342.5 ± 82.7	351.9 ± 76.2
Incidental movement (1-19)	440.3 ± 64.6	437.0 ± 63.9	444.8 ± 65.9
Sporadic movement (20-39)	71.1 ± 17.8	71.8 ± 18.8	70.1 ± 16.6
Purposeful movement (40-59)	27.0 ± 8.6	29.4 ± 9.2	23.7 ± 6.6
Slow walking (60-79)	15.7 ± 7.5	18.2 ± 8.1	12.2 ± 4.7
Medium walking (80-99)	10.4 ± 6.2	12.0 ± 7.1	8.1 ± 3.8
Brisk walking (100-119)	6.4 ± 5.4	7.4 ± 6.5	5.1 ± 3.2
Faster locomotion (120+)	1.4 ± 1.9	1.6 ± 2.1	1.1 ± 1.6

Values are means ± standard deviations.

**Table 3.** Associations of sedentary time, physical activity and steps (measured with Euclidian norm minus one metric in hip) with neurotrophic factors (n=97).

	BDNF (ng/ml)		VEGF (pg/ml)†		IGF-1 (ng/ml)	
	$\beta$	P	$\beta$	P	$\beta$	P
<i>Sedentary time (min/day)</i>	-0.147	0.107	-0.078	0.479	0.130	0.192
<i>Physical activity</i>						
<i>(min/day)</i>						
Light PA	0.242	<b>0.006</b>	0.207	<b>0.048</b>	-0.187	0.055
Moderate PA	0.237	<b>0.016</b>	0.148	0.203	-0.095	0.385
Vigorous PA	0.098	0.343	0.156	0.195	-0.018	0.875
MVPA	0.234	<b>0.019</b>	0.159	0.180	-0.091	0.413
<i>Steps</i>						
Total number of	0.182	0.055	0.110	0.331	-0.105	0.314
steps/day						
Peak 60-min cadence	0.195	<b>0.037</b>	0.055	0.621	-0.061	0.556
(steps/min)						
Peak 30-min cadence	0.171	0.064	0.039	0.724	-0.036	0.724
(steps/min)						
Peak 1-min cadence	0.034	0.720	-0.041	0.712	-0.046	0.658
(steps/min)						

$\beta$  values are standardized. These analyses were adjusted for the following covariates: sex, peak height velocity, fat mass index, wave of participation and parental educational level. The bold font is used to highlight significance level at  $P < 0.05$ . PA=Physical activity; MVPA=Moderate-to-vigorous physical activity; BDNF=Brain-derived neurotrophic factor; VEGF=Vascular endothelial growth factor A; IGF-1=Insulin-like growth factor-

1. †Sample for VEGF was n=88 (n=53 boys; n=35 girls). Normalized values were used in the analyses.

**Supplemental digital content 1.** Data processing of sedentary time and physical activity measurements.

Raw data collected at a sampling frequency of 100 Hz were loaded in ActiLife (ActiGraph, Pensacola, FL, USA) and processed then in R (v. 3.1.2, [https:// www.cran.r-project.org/](https://www.cran.r-project.org/)) using the GGIR package (v. 1.5-12, <https://cran.r-project.org/web/packages/GGIR/>) (1). We calculated the Euclidean Norm Minus One G metric (ENMO,  $1\text{ G} \sim 9.8\text{ m/s}^2$ ) after auto-calibrating the acceleration signal (1,2). The mean of ENMO with negative values rounded to zero was calculated over 5s epochs. Simultaneously, we derived the number of steps/minute (step cadence) from the hip-worn accelerometer from the ActiLife software. Additionally, waking up, and sleeping times were recorded during the 7 days on a diary by the participant.

Accelerometric information processing in GGIR consisted in: 1) non-wear time detection by the Van Hees et al. approach (3); 2) detection of abnormally and sustained high acceleration values (i.e., clipped time); 3) replacement of the non-wear and clipped time by the mean acceleration recorded within the same time frame for the rest of the measurement (3). A replacement by 0 for all metrics was performed if no data were collected for a specific time frame for the rest of the days; 4) identification of waking and sleeping hours based on an automatized algorithm guided by the diaries completed by the participants (4). The inclusion criterion for a valid day was wearing the accelerometer with  $\geq 600$  min/day of waking hours and  $\geq 240$  min/day of sleeping hours. A minimum of 4 valid days (3 weekdays and 1 weekend day) per week was required to be included in the analyses. The compliance wearing the accelerometer was high, with 98% of the sample wearing the accelerometers for  $\geq 6$  days.

Sedentary time and PA were classified into different intensities following Hildebrand et al. hip- and wrist-based cut-off points for the Euclidean Norm Minus One (ENMO) metric (5,6).

All accelerometer data were processed in R by using the GGIR package v.1.5-24 (<https://cran.r-project.org/web/packages/GGIR/>). Steps estimations were derived from ActiLife and then imported to R for further analyses in the GGIR package.

## References

1. van Hees VT, Gorzelniak L, Dean León EC, et al. Separating movement and gravity components in an acceleration signal and implications for the assessment of human daily physical activity. *PLoS One*. 2013;8(4):e61691.
2. van Hees VT, Fang Z, Langford J, et al. Autocalibration of accelerometer data for free-living physical activity assessment using local gravity and temperature: an evaluation on four continents. *J Appl Physiol*. 2014;117(7):738–44.
3. van Hees VT, Renström F, Wright A, et al. Estimation of daily energy expenditure in pregnant and non-pregnant women using a wrist-worn tri-axial accelerometer. *PLoS One*. 2011;6(7):e22922.
4. van Hees VT, Sabia S, Anderson KN, et al. A novel, open access method to assess sleep duration using a wrist-worn accelerometer. *PLoS One*. 2015;10(11):e0142533.
5. Hildebrand M, Hansen BH, van Hees VT, Ekelund U. Evaluation of raw acceleration sedentary thresholds in children and adults. *Scand J Med Sci Sports*. 2016;27(12):1814–23.

6. Hildebrand M, Van Hees VT, Hansen BH, Ekelund U. Age group comparability of raw accelerometer output from wrist-and hip-worn monitors. *Med Sci Sport Exerc.* 2014;46(9):1816–24.



**Table S1.** Associations between sedentary time, physical activity, measured with Euclidian norm minus one metric in non-dominant wrist, and neurotrophic factors (n=97).

	BDNF (ng/ml)		VEGF (pg/ml)†		IGF-1(ng/ml)	
	$\beta$	P	$\beta$	P	$\beta$	P
<i>Sedentary time (min/day)</i>	-0.097	0.288	-0.055	0.609	0.074	0.460
<i>Physical activity (min/day)</i>						
Light PA	0.022	0.801	0.073	0.478	-0.028	0.775
Moderate PA	0.220	<b>0.041</b>	0.071	0.577	-0.078	0.516
Vigorous PA	0.244	<b>0.032</b>	0.229	0.088	-0.054	0.666
MVPA	0.246	<b>0.027</b>	0.110	0.406	-0.080	0.516

$\beta$  values are standardized. These analyses were adjusted for the following covariates: sex, peak height velocity, fat mass index, wave of participation and parental educational level. The bold font is used to highlight significance level at  $P < 0.05$ . PA=Physical activity; MVPA=Moderate-to-vigorous physical activity; BDNF=Brain-derived neurotrophic factor; VEGF=Vascular endothelial growth factor A; IGF-1=Insulin-like growth factor-1. †Sample for VEGF was n=88 (n=53 boys; n=35 girls). Normalized values were used in the analyses.